European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

Blood
David MarinJane F Apperley

Abstract

The majority of patients with chronic myeloid leukemia in chronic phase gain substantial benefit from imatinib but some fail to respond or lose their initial response. In 2006, the European LeukemiaNet published recommendations designed to help identify patients responding poorly to imatinib. Patients were evaluated at 3, 6, 12, and 18 months and some were classified as "failure" or "suboptimal responders." We analyzed outcomes for 224 patients with chronic myeloid leukemia in chronic phase treated in a single institution to validate these recommendations. Patients were followed for a median of 46.1 months. At each time point, patients classified as "failure" showed significantly worse survival, progression-free survival, and cytogenetic response than other patients; for example, based on the assessment at 12 months, the 5-year survival was 87.1% versus 95.1% (P = .02), progression-free survival 76.% versus 90% (P = .002), and complete cytogenetic response rate 26.7% versus 94.1% (P < .001). Similarly, the criteria for "suboptimal response" at 6 and 12 months identified patients destined to fare badly, although criteria at 18 months were less useful. The predictive value of some other individual criteria varied. In general, the...Continue Reading

References

Apr 1, 1988·Cancer·H M KantarjianE J Freireich
Mar 29, 2002·Acta Haematologica·Jaspal KaedaJohn M Goldman
Oct 10, 2003·The New England Journal of Medicine·Tim P HughesUNKNOWN International Randomised Study of Interferon versus STI571 (IRIS) Study Group
Jun 16, 2006·The New England Journal of Medicine·Moshe TalpazCharles L Sawyers
Jun 16, 2006·The New England Journal of Medicine·Hagop KantarjianOliver G Ottmann
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators
Jun 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hugues de LavalladeDavid Marin
Jul 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jamshid S KhorashadDavid Marin

❮ Previous
Next ❯

Citations

Aug 15, 2013·Journal of Cancer Research and Clinical Oncology·Andreas Hochhaus, Hagop Kantarjian
Oct 12, 2011·International Journal of Clinical Oncology·Chikashi YoshidaHisashi Sakamaki
Oct 2, 2013·Wiener medizinische Wochenschrift·Thomas LionGünther Gastl
Apr 29, 2010·Current Hematologic Malignancy Reports·Meetu AgrawalAlfonso Quintás-Cardama
Apr 29, 2010·Current Hematologic Malignancy Reports·Maxim Norkin, Charles A Schiffer
Mar 31, 2011·Current Hematologic Malignancy Reports·Deborah L White, Timothy P Hughes
Mar 8, 2012·Current Hematologic Malignancy Reports·Meinolf SuttorpFrederic Millot
Feb 6, 2013·Current Hematologic Malignancy Reports·David Marin
Jul 24, 2012·Current Oncology Reports·Carmen FavaGiuseppe Saglio
Jan 5, 2010·ACS Chemical Biology·Ratika Krishnamurty, Dustin J Maly
Jul 25, 2012·Nature Reviews. Cancer·Thomas O'HareMichael W Deininger
Sep 30, 2010·Nature Reviews. Clinical Oncology·Massimo Breccia
Sep 16, 2011·Current Opinion in Oncology·Bhuvan Kishore, David Marin
Jan 12, 2010·Current Opinion in Hematology·Michael Osborn, Timothy Hughes
Jan 22, 2011·Current Opinion in Hematology·Ross A Okimoto, Richard A Van Etten
Jan 22, 2013·Current Opinion in Hematology·David MarinJohn Goldman
Dec 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas O'Hare, Michael W Deininger
Dec 17, 2009·Hematology·John M Goldman
Apr 1, 2011·Blood·Gabriele GugliottaUNKNOWN Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party
Jun 14, 2012·Blood·Simona LuattiUNKNOWN Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML
Oct 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elias JabbourJorge E Cortes
Nov 5, 2010·Haematologica·Rüdiger HehlmannUNKNOWN European LeukemiaNet
Oct 26, 2010·Haematologica·Jane R EnglerDeborah L White
Aug 2, 2013·Haematologica·Angelo M CarellaJohn M Goldman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.